ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca

Some seven weeks after announcing top-line data, Novartis is unveiling more details on its momentum-building rare disease drug, iptacopan, specifically a head-to-head phase 3 victory against AstraZeneca’s anti-C5 competition. And the Big Pharma is emphasizing the drug’s benefit as a standalone therapy as it expands development.